Working… Menu

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00675077
Recruitment Status : Unknown
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 8, 2008
Last Update Posted : January 5, 2009
Information provided by:
GAAD Medical Research Institute Inc.

Brief Summary:

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Condition or disease Intervention/treatment Phase
Huntington Disease Radiation: Far Infrared Radiation Phase 1

Detailed Description:

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD
Study Start Date : May 2008
Estimated Primary Completion Date : May 2010
Estimated Study Completion Date : June 2010

Arm Intervention/treatment
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)

Primary Outcome Measures :
  1. Treatment of people with HD [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Rehabilitation of people with HD [ Time Frame: 2 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • People with HD

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00675077

Layout table for location information
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Layout table for investigator information
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.

Layout table for additonal information
Responsible Party: Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc. Identifier: NCT00675077     History of Changes
Other Study ID Numbers: GAAD-HD-CTP1
First Posted: May 8, 2008    Key Record Dates
Last Update Posted: January 5, 2009
Last Verified: January 2009
Keywords provided by GAAD Medical Research Institute Inc.:
Akinetic-Rigid Variant of Huntington Disease
Chorea, Chronic Progressive Hereditary (Huntington)
Chronic Progressive Hereditary Chorea (Huntington)
Huntington Chorea
Huntington Chronic Progressive Hereditary Chorea
Huntington Disease, Akinetic-Rigid Variant
Huntington Disease, Juvenile
Huntington Disease, Juvenile-Onset
Additional relevant MeSH terms:
Layout table for MeSH terms
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders